Roche spends $1 billion on Foundation Medicine’s tumor profiling
With companion diagnostics' growing importance in the development of precision medicines, pharma's interest in gaining stakes in diagnostics companies makes sense. “Pharma companies are deep-pocketed partners with a great deal of FDA experience, and the agency eventually wants to regulate LDTs,” says Marc Samuels, president and CEO of ADVI, a Washington, DC–based healthcare advisory services firm. “Greater ownership of a diagnostics firm allows a pharma to better manage and control the fate of its pipeline in an era where biomarkers are the key to faster approvals with smaller clinical trials.”
Roche spends $1 billion on Foundation Medicine’s tumor profiling
[el-text]
With companion diagnostics’ growing importance in the development of precision medicines, pharma’s interest in gaining stakes in diagnostics companies makes sense. “Pharma companies are deep-pocketed partners with a great deal of FDA experience, and the agency eventually wants to regulate LDTs,” says Marc Samuels, president and CEO of ADVI, a Washington, DC–based healthcare advisory services firm. “Greater ownership of a diagnostics firm allows a pharma to better manage and control the fate of its pipeline in an era where biomarkers are the key to faster approvals with smaller clinical trials.”
[/el-text]
[el-text]
View full article here
Reach out
Own your edge
We don’t just guide the market. We shape it. Map your market access moves with #ADVIIntelligence. Proven advantage. Unmatched partnership.